1.. INTRODUCTION
================

In physiological conditions, about 1500 mmol of lactate is produced daily from various organs, including the muscles, intestine, red blood cells, brain and skin ([@ref1]). Lactate is metabolized by the liver (about 60 %), the kidneys (about 30 %), and other organs. Normal blood lactate concentration is around 1 mmol/L ([@ref2]).One of the most important metabolic changes due to lack of oxygen is the Pasteur effect ([@ref3]). Due to oxygen shortage, pyruvate derived from the anaerobic conversion of glucose cannot enter the Krebs' cycle via acetyl-coenzyme A to produce energy ([@ref3]). The conversion of pyruvate to lactate allows energy production without oxygen ([@ref3]). This is the most important adaptive mechanism to survive hypoxia ([@ref3]).

Hyperlactatemia is defined as a lactate measurement \> 2 mmol/L, and is common in critical illness ([@ref4]). Lactate should not be regarded as toxic or harmful by itself. Although frequently used to diagnose in adequate tissue oxygenation, other processes not related to tissue oxygen at ion may increase lactate levels ([@ref4]). Especially in critically ill patients, increased glycolysis maybe an important cause of hyperlactatemia ([@ref5]). Hyperlactatemia has been described as a hallmark characteristic of shock states ([@ref6]). The metabolism of lactate in critically ill patients has also been associated with cellular inflammatory response ([@ref7]). Repeated lactate measurements over time may be more useful for clinicians rather than a single lactate measurement for risk stratification in critically ill patients. Although the suggested optimal timing of lactate measurements is not precisely defined, the importance of repeated lactate measurements in critically ill patients is based on a time window in which the hypoxic cells return to a normal state if oxygen is supplied. Some studies reported that 6-hourly changes could be a useful guide ([@ref8], [@ref9]) while other suggest longer time intervals of 12--24 hours ([@ref10], [@ref11]). his time frame is the opportunity for the patient to receive treatment to save the cells and organs from irreversible damage.

2.. OBJECTIVE
=============

The aim of the study was to describe the prevalence of hyperlactatemia and emphasis on repeated lactate measurements in critically ill patients, and the associated mortality.

3.. MATERIAL AND METHODS
========================

Ninety-four patients were admitted to the 7-bed Medical Intensive Care Unit, Clinical Center, University of Sarajevo, between July and December 2015. Of these, 12 patients died within 24 hours of admission, and another 12 patients were excluded from the study due to incomplete laboratory data. The remaining 70 patients were included in the study. The patients were admitted from the emergency department or from a hospital ward. The reasons for admission were grouped in to five diagnoses: sepsis/septic shock, cardiogenic shock, respiratory failure, neurological and other causes. When multiple diagnoses were present, the leading one with the worst prognosis was selected as the main reason for admission. For each patient, the following data were collected: age, gender, Simplified Acute Physiology Score (SAPS) II, Acute Physiology and Chronic Health Evaluation (APACHE) II, lactate concentrations upon admission, after 24 and 48 hours, and at the clinical outcomes. Based on the clinical outcomes, patients were divided into two groups: survivors, a) patients who were discharged from the hospital, and b) non-survivors, i.e. patients who died during the hospitalization.

Statistical analyses were performed retrospectively and anonymously. Routine collection of data did not interfere with patient care and treatment in any way. Data were tabulated for continuous variables as means and standard deviation, and for categorical variables as absolute and relative frequencies. Logistic regression was done with lactate concentration categorical variable as the outcome measure in a single regression analysis. ANOVA test was performed for repeated lactate measurements at 0h, 24h and 48h. A receiver operating characteristic (ROC) curve was used to determine a cut-off value for the sensitivity and specificity of lactate concentration for prediction of mortality. Statistical significance was p ≤ 0.05. Graphically, data were presented in tables and figures. Data were analyzed using SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).

4.. RESULTS
===========

Out of 70 patients included in the study, there were 44 (62.9%) survivors and 26 (37.1%) non-survivors. Baseline patient characteristics and survival prediction scores are presented in [Table 1](#table1){ref-type="table"}. Hyperlactatemia (serum lactate \> 2 mmol/L) upon admission was present in 64 (91.4%) of the admitted patients, with mean lactate concentration 4.13 ±1.21 mmol/L. The reasons for admission and lactate concentrations at admission are presented in [Table 2](#table2){ref-type="table"}. Mean lactate level values in survivors and non-survivors are presented in [Table 3](#table3){ref-type="table"}. By using Anova test, the statistically significant difference was established in the mean lactate values at 0h, 24h and 48h between survivors and non-survivors.

To evaluate the effect of the lactate values on the patient outcome, regression analysis was used ([Table 4](#table4){ref-type="table"}).

Lactate concentration at 48 hours was independently associated with increased in-hospital mortality (OR 6.68, 95% (CI) 1.38 to 32.25, P = 0.018). Further analysis showed that lactate concentration at 48 hours represents a statistically significant predictive marker of fatal outcomes of patients (area under the curve of 0.874, CI 0.769-0.980 p = 0.001) (Figure 1). The cut-off value for LAC 48h was 2.25 mmol/L, with sensitivity of 0.722 and specificity of 0.921.

5.. DISCUSSION
==============

In our study, the mortality rate of critically ill patients, admitted to the medical ICU, was 37.1%, which is similar to or lower than the mortality rate reported in previous studies ([@ref12]). Upon admission, hyperlactatemia was present in 91.4% of critically ill patients. Previous studies investigated the impact of hyperlactatemia on mortality in patients admitted to the ICU, and reported cumulative prevalence rates of 10 to 70% ([@ref13], [@ref14]). Such a high occurrence of hyperlactatemia at admission in the patients in our study might be explained by the possibility that they were admitted to the ICU at a more advanced stage in their clinical conditions.

In our study, the mean lactate concentration upon admission was 4.13 ±1.21 mmol/L in critically ill patients. A previous study showed that an initial lactate level of more than 4.0 mmol/L substantially increases the probability of acute-phase death ([@ref15]). Kliegel et al. showed that their survivors had lower lactate levels on admission than that found in our study ([@ref16]). In our study, patients with sepsis/septic shock had a mean lactate concentration of 5.01 ±2.19 mmol/L. Haas et al. found that the degree of hyperlactatemia was directly related to the severity of the shock state and to mortality rates ([@ref17]). Previous studies in patients with sepsis confirmed the impact of persistent hyperlactatemia on the poor clinical outcomes ([@ref18], [@ref19]). Patients that with cardiogenic shock had a mean lactate concentration of 5.91 ±2.40 mmol/L. Previous studies in patients with cardiogenic shock showed that lactate concentrations decreased more in survivors than in non-survivors ([@ref20], [@ref21]). Increased lactate concentrations may be due to other factors than just cellular hypoxia ([@ref22]). Use of beta-adrenergic stimulation may contribute to increased lactate production ([@ref22]).

In our study, there was statistically significant difference in the mean lactate concentration at admission, after 24 hours and 48 hours between survivors versus non-survivors. Our results are consistent with those reported by Mikkelsen et al. ([@ref23]). In spite of prevailing evidence that the lactate reduction influences the critically ill patient outcomes, there are five studies reporting no predictive effect of a decrease in lactate levels over time on mortality ([@ref24], [@ref25], [@ref26], [@ref27], [@ref28]). Although they showed no effect on mortality, the study by Manikis et al ([@ref24]) and Billeteret al ([@ref25]) suggested a relationship between lactate concentration and morbidity outcomes.

In our study, lactate levels at 48 hours were the independent predictor for mortality, with a cut-off value of 2.25 mmol/L, and sensitivity of 72.2 % and specificity of 92.1%. The study by Kliegel et al. also showed that lactate concentration at 48 hours was an independent predictor for mortality. In their study, lactate levels higher than 2 mmol/Lafter 48 hours predicted mortality, with a specificity of 86% and sensitivity of 31% ([@ref16]). The measurements of lactate concentration were spaced 24 hours apart (0h, 24h, 48h). Several studies report that a shorter time frame, ie. every six hour intervals in lactate concentration, could be a more accurate clinical guide ([@ref29], [@ref30]). In the study by Haas et al, lactate elimination after 12 h showed a good predictive effect on mortality in the ICU. In that study, the ICU patients whose lactate elimination was at 32.8%, had a mortality rate of 96.6% ([@ref17]). Our study was observational, and as such did not include the effect of therapeutic interventions on the lactate kinetics. An interventional trial by Jansenet al. targeted a lactate decrease of at least 20 % in 2 hours for the initial 8 hours of treatment in ICU patients with an initial lactate concentration of≥ 3 mmol/L. This strategy was associated with a lower mortality rate for the lactate-guided therapy ([@ref31]). In another interventional study, the patients were managed according to the same protocol by reducing lactate levels to \<2.4 mmol/L. Failure to achieve this target was associated with an increased risk of infection, length of hospital stay, and mortality ([@ref32]). Measuring blood lactate to assess the efficacy of therapy has also been shown by Rivers et al ([@ref33]). A rapid rate of lactate elimination and an earlier time of resolution of hyperlactatemia has been associated with increased survival rate ([@ref34]). Although changes in blood lactate kinetics were clearly significant after 6 hours in many studies and after 12 hours in most, it is currently not clear what the best time interval between lactate measurements should be. A decrease in blood lactate following a therapeutic intervention is a major indicator of the efficacy of the treatment. This means that repeated lactate measurement may be used as a guide to therapy. If blood lactate concentrations do not normalize over time, the need for alternative therapy should be considered.

*Limitations of the study.* Our relatively small sample size and being a single center study were limiting factors.

*Advantages of the study.* This study offers several advantages, including an objective basis for repeated measurements of blood lactate concentration and its impact on the clinical outcomes, especially focusing on critically ill patients. In our country not so much research in this field.

6.. CONCLUSION
==============

Blood hyperlactatemia is common in critically ill patients and at 48 hours is independently associated with an increase in mortality in hospitals and it represents a statistically significant predictive marker of fatal clinical outcomes for critically ill patients. Blood lactate concentrations\> 2.25 mmol/L can be regarded by clinicians to identify patients at high mortality risk.
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###### Baseline patient characteristics and survival prediction scores

                           Survivors (n=44)   Non-survivors (n=26)   P
  ------------------------ ------------------ ---------------------- --------
  Age (years)              59.1±18.2          66.5±16.4              0.094
  Malespatients, *n* (%)   16 (36.3)          11 (42.3)              0.766
  SAPS II                  43.1±11.5          64.5±16.8              0.0001
  APACHE II                19.4±7.2           28.0±8.3               0.0001

###### Reasons for admission into the medical ICU and lactate measurements at admission.

  Reasonsforadmission    Patients, n (%)   Meanlactateconcentration (mmol/L)
  ---------------------- ----------------- -----------------------------------
  Sepsis / septicshock   16 (22.9)         5.01 ±2.19
  Cardiogenicshock       15 (21.4)         5.91 ±1.94
  Respiratoryfailure     24 (34.3)         3.42 ±0.7
  Neurologicalcauses     10 (14.3)         2.72 ±0.93
  Othercauses            5 (7.1)           3.61 ±1.44

###### Comparisonofmeanlactatelevels at 0h, 24h and 48h betweensurvivorsandnon-survivors. LAC= lactate concentration

                      N           Mean (mmol/L)   SD     SEM    95% Confidence Interval for Mean   Minimum (mmol/L)   Maximum (mmol/L)           
  ------------------- ----------- --------------- ------ ------ ---------------------------------- ------------------ ------------------ ------- ------
  LAC 0h              Survivors   44              3,64   1,60   ,24                                3,1596             4,1359             1,10    8,10
  Non-survivors       26          4,88            2,78   ,54    3,7626                             6,0143             1,10               11,30   
  F=5.608; p=0.021                                                                                                                               
  LAC 24h             Survivors   39              2,40   1,49   ,23                                1,9169             2,8883             ,70     8,20
  Non-survivors       23          4,00            2,76   ,57    2,8085                             5,2001             ,70                12,00   
  F=8.784; p=0.004                                                                                                                               
  LAC 48h             Survivors   38              1,50   ,52    ,08                                1,3281             1,6719             ,60     2,50
  Non-survivors       18          3,54            2,39   ,56    2,3543                             4,7345             1,40               9,80    
  F=25.649; p=0.001                                                                                                                              

###### Effectofthelactatevalues on thepatientoutcome LAC= lactate concentration

             B        S.E.    Wald     df     Sig.   Exp(B)   95% CI, EXP(B)            
  ---------- -------- ------- -------- ------ ------ -------- ---------------- -------- -------
  Step 1a    LAC 0h   ,131    ,207     ,401   1      ,527     1,140            ,760     1,711
  LAC 24h    ,108     ,283    ,145     1      ,704   1,114    ,639             1,941    
  LAC 48h    1,900    ,803    5,606    1      ,018   6,689    1,387            32,252   
  Constant   -5,452   1,575   11,977   1      ,001   ,004                               
